Plain-English translation of NCT06187506 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for people with high-risk, early-stage bladder cancer. The study combines a new drug called — a targeted therapy designed to attack cancer cells with a specific protein marker — with BCG immunotherapy, which is a standard treatment that helps your immune system fight cancer. Researchers want to see if using both treatments together can prevent cancer from returning or progressing.
Many people with high-risk early-stage bladder cancer are told their best option is surgery to remove the bladder, but some patients cannot have surgery or prefer not to. This medication offers a new option for these patients, combining targeted therapy with proven immunotherapy to try to control the cancer without removing the bladder.
You would receive the new medication intravenously every three weeks for 6 months, along with BCG immunotherapy given directly into your bladder. BCG starts with weekly instillations for 6 weeks, followed by maintenance doses at 3, 6, and 12 months. You would have frequent follow-up visits including bladder scans (cystoscopy) and urine tests every 3 months for the first 2 years, then every 6 months afterward, plus imaging scans every 6 months for 2 years and then yearly. The total commitment is at least 2 years of active monitoring.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China